TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Sai Life Sciences Ltd.

SAILIFE on NSE · 19 Nov 2026

NIFTY 500

1,788.40 ▲ +0.02 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Guidance tracker

What SAILIFE guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
12 Nov 2026Sai Life Sciences filed the transcript of its Q2 FY27 earnings conference call held on 6 November 2026, following its unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Management said Q2 FY27 revenue grew 23% year-on-year (CDMO up 20%, CRO up 28%), and H1 FY27... NSE copy No results filed since
06 Nov 2026Sai Life Sciences filed the investor presentation for its unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026), to be used at an earnings call on 6 November 2026 at 11:00 AM IST. Q2 FY27: revenue ₹659 Cr (up 23% YoY), material margin ₹484 Cr (up 22% YoY),... NSE copy No results filed since
12 Aug 2026Sai Life Sciences filed the transcript of its Q1 FY27 earnings conference call held on 7 August 2026, following its unaudited results for the quarter ended 30 June 2026. Management said Q1 revenue was INR553 crores, up about 12% year-on-year from INR496 crores, with CRO revenue up about 26% and CDMO revenue up... NSE copy +17.3 %+22.5 %+12.0 %
07 Aug 2026Sai Life Sciences filed its investor presentation for the quarter ended 30 June 2026 (Q1FY27). Q1FY27 revenue was ₹554 crore, up 12% year-on-year; material margin ₹409 crore (up 15%); EBITDA ₹148 crore (up 18%); PAT ₹73 crore (up 22%). Capex incurred was ₹263 crore; capacity utilization 65%. CRO business grew 24%... NSE copy +17.3 %+22.5 %+12.0 %
15 May 2026Sai Life Sciences filed its investor presentation for the quarter and year ended 31 March 2026. Management (MD & CEO Krishna Kanumuri) said FY26 was an important year, with deeper relationships with global pharma customers and expanded integrated CRDMO capabilities, and that long-term outsourcing fundamentals... NSE copy +21.2 %+11.7 %-3.4 %
06 Feb 2026Sai Life Sciences filed its investor presentation for Q3 and nine months ended 31 December 2025. Q3FY26 total revenue was ₹556 Cr, up 27% year-on-year from ₹440 Cr; EBITDA was ₹191 Cr, up 54% from ₹124 Cr, with margin up 605 bps to 34%; PAT was ₹100 Cr, up 86% from ₹54 Cr. CDMO revenue was ₹361 Cr (up 31% from ₹276... NSE copy ---1.9 %
21 May 2025Sai Life Sciences filed the transcript of its Q4 and FY25 earnings call, held on 14 May 2025, under Regulation 30 of SEBI LODR. Management said FY25 revenue from operations was around INR1,695 crores, up 16% from INR1,465 crores in FY24, with EBITDA of INR425 crores (25% margin, up from 20%) and PAT of INR170... NSE copy --+4.6 %
25 Feb 2025Sai Life Sciences filed an updated investor presentation for the quarter ended 31 December 2024 (Q3 FY25), adding a revenue split between CRO and CDMO activities at the request of investors. Q3 FY25 revenue from operations was ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3 FY24; EBITDA was ₹124 Cr with a margin of 28.3%;... NSE copy --+4.6 %
12 Feb 2025Sai Life Sciences filed the transcript of its Q3 FY25 earnings conference call, held on 07 February 2025, on the unaudited results for the quarter and nine months ended 31 December 2024. Management (CEO Krishna Kanumuri, CFO Siva Chittor) said Q3 revenue from operations rose 15% year-on-year to 440 crores, with... NSE copy --+4.6 %
07 Feb 2025Sai Life Sciences filed its investor update presentation for the quarter ended 31 December 2024 (Q3 FY25). Q3 FY25 revenue from operations was ₹439.8 Cr, up 15% from ₹383.6 Cr in Q3 FY24; EBITDA was ₹124 Cr (28.3% margin) and PAT was ₹53.9 Cr, up from ₹39.6 Cr. For 9MFY25, revenue was ₹1,115 Cr (up 9% YoY), EBITDA... NSE copy --+4.6 %

Filings tagged as guidance, newest first (10 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
13 Nov 2026Credit ratingSai Life Sciences filed a credit rating update under Regulation 30: India Ratings & Research upgraded its long-term bank loan facilities rating to IND AA (Stable) from IND AA- (Positive) on 13 November 2026, for rated limits of INR 7,690 million. The short-term rating was affirmed at IND A1+. India Ratings cites... NSE copy
05 Nov 2026Management changeSai Life Sciences Limited filed the outcome of its board meeting held on 05 November 2026. The board approved the unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026, with limited review reports enclosed. The board appointed Mr. Sidhartha Das as... NSE copy
26 Feb 2026Credit ratingSai Life Sciences Limited filed an intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015, enclosing a credit rating letter from ICRA Limited dated 26 February 2026. ICRA assigned [ICRA]AA (Stable) to long-term fund-based (others) facilities of Rs. 550.00 crore and [ICRA]A1+ (Stable) to short-term... NSE copy
14 Aug 2025Credit ratingSai Life Sciences filed under Regulation 30 to intimate that India Ratings & Research (Fitch Group) upgraded its ratings of the company on 14 August 2025. Bank loan facility of INR 7,690 million (reduced from INR 11,800 million) rated IND AA-/Positive/IND A1+, upgraded from IND A+/Stable/IND A1+; short-term rating... NSE copy
07 Aug 2025Management changeBoard of Sai Life Sciences approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, with a limited review report from Deloitte Haskins & Sells LLP (unmodified conclusion). Standalone revenue from operations for Q1 FY26 was Rs 4,830.38 million, against Rs 2,644.69 million... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (5 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in